title: [Factors associated with quality of life in survivors of gestational trophoblastic neoplasm after chemotherapy].
abstract: OBJECTIVE
  To measure the quality of life (QoL) of gestational trophoblastic neoplasia (GTN) survivors after chemotherapy by using a self-invented scale, and to explore the factors associated with QoL.
  
  
  METHODS
  The design of questionnaire was based on a series of internationally valid QoL scales, which was tested by epidemiology and showed good reliability and validity. A total of 100 survivors of GTN patients from Peking Union Medical College Hospital participated in this survey from December 2008 to May 2009.
  
  
  RESULTS
  Patients with disease-free more than three months after chemotherapy enjoys a good QoL, while only 16% (16/100) of survivors feel general overall QoL, but no one feels bad QoL. As refer to sexual function, more than half of these patients (70%, 70/100) satisfied with their sexual life, while there were still 47% (47/100) and 45% (45/100) of the patients complaining of decreased sexual desire and dryness of vagina. 66% (66/100) of the GTN survivors expressed depression, and 50% (50/100) of patients complained anxiety, which were potential factors influencing QoL of GTN survivors. Relevant analysis explored the possible predictors of QoL for GTN patients, including physical function (r = 0.609, P < 0.01), sexual function (r = 0.473, P < 0.01), and social psychology (r = 0.294, P < 0.01).
  
  
  CONCLUSIONS
  GTN survivors have an overall good QoL after chemotherapy, the possible predictors of QoL for GTN patients include physical function, sexual function and social psychology. The sexual dysfunctions mostly present with short of sexual desire and dryness of vagina. Fear of recurrence may be a potential factor influencing QoL a long term after remission.
authors.affiliation: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Mei-ying
authors.initials: MY
authors.lastname: Quan
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiang
authors.forename: Xi-run
authors.initials: XR
authors.lastname: Wan
authors.forename: Feng-zhi
authors.initials: FZ
authors.lastname: Feng
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003866:Depressive Disorder / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology*; D006306:Health Surveys; D006801:Humans; D008599:Menstruation Disturbances / Q000453:epidemiology / Q000209:etiology; D008875:Middle Aged; D011247:Pregnancy; D011379:Prognosis; D011788:Quality of Life; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology / Q000209:etiology; D012944:Social Support; D011795:Surveys and Questionnaires; D017741:Survivors; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents